DRNA
Income statement / Annual
Last year (2020), Dicerna Pharmaceuticals, Inc.'s total revenue was $164.31 M,
an increase of 587.36% from the previous year.
In 2020, Dicerna Pharmaceuticals, Inc.'s net income was -$112.75 M.
See Dicerna Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$164.31 M |
$23.90 M |
$6.18 M |
$2.28 M |
$295.00 K |
$184.00 K |
$0.00 |
$0.00 |
$7.02 M |
$7.91 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$164.31 M
|
$23.90 M
|
$6.18 M
|
$2.28 M
|
$295.00 K
|
$184.00 K
|
$0.00
|
$0.00
|
$7.02 M
|
$7.91 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$205.38 M
|
$109.34 M
|
$45.71 M
|
$36.98 M
|
$41.69 M
|
$43.97 M
|
$29.45 M
|
$11.56 M
|
$11.57 M
|
$10.71 M
|
| General & Administrative Expenses |
$72.13 M
|
$42.75 M
|
$21.69 M
|
$25.88 M
|
$18.35 M
|
$19.24 M
|
$15.65 M
|
$5.82 M
|
$4.70 M
|
$4.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$72.13 M
|
$42.75 M
|
$21.69 M
|
$25.88 M
|
$18.35 M
|
$19.24 M
|
$15.65 M
|
$5.82 M
|
$4.70 M
|
$4.82 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$277.52 M
|
$152.09 M
|
$67.40 M
|
$62.86 M
|
$60.04 M
|
$63.21 M
|
$45.10 M
|
$17.38 M
|
$16.27 M
|
$15.52 M
|
| Cost And Expenses |
$277.52 M
|
$152.09 M
|
$67.40 M
|
$62.86 M
|
$60.04 M
|
$63.21 M
|
$45.10 M
|
$17.38 M
|
$16.27 M
|
$15.52 M
|
| Interest Income |
$6.01 M
|
$7.54 M
|
$2.10 M
|
$539.00 K
|
$235.00 K
|
$188.00 K
|
$63.00 K
|
$4.00 K
|
$2.00 K
|
$3.00 K
|
| Interest Expense |
$20.00 K
|
$3.00 K
|
$603.00 K
|
$0.00
|
$0.00
|
$0.00
|
$199.00 K
|
$952.00 K
|
$1.34 M
|
$997.00 K
|
| Depreciation & Amortization |
$2.22 M
|
$1.25 M
|
$774.00 K
|
$778.00 K
|
$840.00 K
|
$727.00 K
|
$848.00 K
|
$523.00 K
|
$551.00 K
|
$474.00 K
|
| EBITDA |
-$110.51 M |
-$119.20 M |
-$87.48 M |
-$59.27 M |
-$58.67 M |
-$62.11 M |
-$46.89 M |
-$17.04 M |
-$8.23 M |
-$7.09 M |
| EBITDA Ratio |
-0.67
|
-4.99
|
-14.16
|
-26.03
|
-198.89
|
-337.57
|
0
|
0
|
-1.17
|
-0.9
|
| Operating Income Ratio |
-0.69
|
-5.36
|
-9.91
|
-26.61
|
-202.54
|
-342.54
|
0
|
0
|
-1.32
|
-0.96
|
| Total Other Income/Expenses Net |
$461.00 K
|
$7.73 M
|
-$27.63 M
|
$539.00 K
|
$235.00 K
|
$188.00 K
|
-$2.84 M
|
-$1.14 M
|
-$871.00 K
|
-$943.00 K
|
| Income Before Tax |
-$112.75 M
|
-$120.46 M
|
-$88.85 M
|
-$60.05 M
|
-$59.51 M
|
-$62.84 M
|
-$47.94 M
|
-$18.52 M
|
-$10.12 M
|
-$8.56 M
|
| Income Before Tax Ratio |
-0.69
|
-5.04
|
-14.39
|
-26.37
|
-201.74
|
-341.52
|
0
|
0
|
-1.44
|
-1.08
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$539.00 K
|
$235.00 K
|
$188.00 K
|
$0.00
|
$0.00
|
$0.00
|
$54.00 K
|
| Net Income |
-$112.75 M
|
-$120.46 M
|
-$88.85 M
|
-$60.05 M
|
-$59.51 M
|
-$62.84 M
|
-$47.94 M
|
-$18.52 M
|
-$10.12 M
|
-$8.56 M
|
| Net Income Ratio |
-0.69
|
-5.04
|
-14.39
|
-26.37
|
-201.74
|
-341.52
|
0
|
0
|
-1.44
|
-1.08
|
| EPS |
-1.51 |
-1.76 |
-1.6 |
-2.9 |
-2.87 |
-3.09 |
-2.98 |
-1.11 |
-4.95 |
-0.11 |
| EPS Diluted |
-1.51 |
-1.76 |
-1.6 |
-2.9 |
-2.87 |
-3.09 |
-2.98 |
-1.11 |
-4.95 |
-0.11 |
| Weighted Average Shares Out |
$74.52 M
|
$68.43 M
|
$55.62 M
|
$20.72 M
|
$20.72 M
|
$20.32 M
|
$16.07 M
|
$16.63 M
|
$2.05 M
|
$77.91 M
|
| Weighted Average Shares Out Diluted |
$74.52 M
|
$68.43 M
|
$55.62 M
|
$20.72 M
|
$20.72 M
|
$20.32 M
|
$16.07 M
|
$16.63 M
|
$2.05 M
|
$77.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
